Tryp Therapeutics announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company’s ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.
Compound Psilocybin
Visit article
Category Press Release
Country United States of America
Companies Featured
Tryp TherapeuticsTryp Therapeutics is a clinical stage drug development company developing psilocybin products for various diseases/disorders including fibromyalgia.